The Journal of thoracic and cardiovascular surgery · 2026
Phase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection.
СтатьяКлиническое исследование I фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wolf Andrea S, Gulati Shubham, Dolasia Komal, Fitzgerald Bailey, Gomez Jorge, Yankelevitz David, Salazar Andres, Tsankov Alexander M, Marron Thomas, Flores Raja
Аннотация
OBJECTIVE: To evaluate the role of neoadjuvant injection of the viral mimic poly-ICLC (polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose) in patients with pleural mesothelioma undergoing curative-intent surgical resection.
METHODS: Patients with documented pleural mesothelioma who were deemed resectable underwent intratumoral injection of poly-ICLC 2-4 weeks prior to planned curative-intent surgery. Safety and toxicity were the primary endpoints. Secondary endpoints were postoperative complications, mortality, and overall survival (OS), with patients censored at the date of last follow-up if not known to be deceased.
RESULTS: Between 2020 and 2024, 19 patients underwent treatment followed by pleurectomy/decortication a median of 19 days (range, 14-192 days) later. Poly-ICLC was well tolerated, with drug-related grade I toxicities occurring in 7 patients (37%). All patients were resectable and had the diaphragm and pericardium preserved. The median length of stay was 7 days (range, 3-19 days), postoperative complications were minor, except 1 cardiac arrest due to complete heart block, and there were no deaths within 90 days of surgery. The median OS was 19.6 months from injection (95% confidence interval [CI], 14.7 months to not reached [NR]) and 19.1 months from surgery (95% CI, 13.4 months to NR). One patient in whom surgery was delayed and who underwent systemic chemotherapy following injection was found to have a complete response to poly-ICLC and systemic treatment.
CONCLUSIONS: This prospective clinical trial is the first to demonstrate the safety of intratumoral injection of poly-ICLC with excellent surgical results and favorable survival, with 1 patient experiencing a dramatic response to injection and chemotherapy. The use of poly-ICLC as an immunostimulant with combinatorial strategies offers hope for treating this challenging disease.
METHODS: Patients with documented pleural mesothelioma who were deemed resectable underwent intratumoral injection of poly-ICLC 2-4 weeks prior to planned curative-intent surgery. Safety and toxicity were the primary endpoints. Secondary endpoints were postoperative complications, mortality, and overall survival (OS), with patients censored at the date of last follow-up if not known to be deceased.
RESULTS: Between 2020 and 2024, 19 patients underwent treatment followed by pleurectomy/decortication a median of 19 days (range, 14-192 days) later. Poly-ICLC was well tolerated, with drug-related grade I toxicities occurring in 7 patients (37%). All patients were resectable and had the diaphragm and pericardium preserved. The median length of stay was 7 days (range, 3-19 days), postoperative complications were minor, except 1 cardiac arrest due to complete heart block, and there were no deaths within 90 days of surgery. The median OS was 19.6 months from injection (95% confidence interval [CI], 14.7 months to not reached [NR]) and 19.1 months from surgery (95% CI, 13.4 months to NR). One patient in whom surgery was delayed and who underwent systemic chemotherapy following injection was found to have a complete response to poly-ICLC and systemic treatment.
CONCLUSIONS: This prospective clinical trial is the first to demonstrate the safety of intratumoral injection of poly-ICLC with excellent surgical results and favorable survival, with 1 patient experiencing a dramatic response to injection and chemotherapy. The use of poly-ICLC as an immunostimulant with combinatorial strategies offers hope for treating this challenging disease.